TABLE 7.
Postexposure therapy with neutralizing MAbs after challenge of AG129 mice with DENV-3 16652 (gI)c
| MAb | No. of mice that survived | No. of mice that died | Total no. of mice | % Survival | MTDa | ±SD | P valueb |
|---|---|---|---|---|---|---|---|
| WNV E16 | 0 | 12 | 12 | 0 | 14 | 3.4 | |
| DENV-3-E48 | 0 | 7 | 7 | 0 | 19 | 9.7 | >0.1 |
| DENV-3-E57 | 8 | 3 | 11 | 73 | 14 | 4.0 | <0.001 |
| DENV-3-E59 | 3 | 7 | 10 | 30 | 14 | 5.6 | >0.1 |
| DENV-3-E63 | 10 | 3 | 13 | 77 | 20 | 1.5 | <0.0001 |
a
MTD, mean time to death.
b
P values were calculated using the log rank test by comparing values for the negative-control MAb and antibody-treated mice.
c
Four -to 5-week-old AG129 mice were administered 500 μg of the indicated MAbs 2 days after infection with 5 × 103 PFU of strain 16652 by the i.c. route. Mice were monitored for survival for 60 days after infection.